Vanguard Global Advisers’s Seaport Therapeutics SPTX Stock Holding History

Vanguard Global Advisers’s Portfolio SPTX Stock Details SPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$155K	Buy	+7,159	New	+$126K	﹤0.01%	2599

Other funds holding SPTX

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

TGV

TRV GP VI Boston, Massachusetts $232M AUM 247.08% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Global Advisers's SPTX Position: Q2 2026 in Review

Vanguard Global Advisers opened a new position in Seaport Therapeutics (SPTX) in Q2 2026: 7,159 shares worth $155K. The stake represents ﹤0.01% of the portfolio and ranks #2599 among its holdings.

54 funds tracked by Wall St. Rank hold SPTX as of Q2 2026.

Vanguard Global Advisers held 7,159 shares of Seaport Therapeutics worth $155K as of Q2 2026.
Seaport Therapeutics was a new Vanguard Global Advisers position in Q2 2026.
Seaport Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2599 holding.
54 funds tracked by Wall St. Rank held Seaport Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.